7hon MSN
We recently published a list of 10 Best Performing Mid Cap Stocks to Buy According to Analysts. In this article, we are going ...
We recently published a list of the 10 Best Performing Pharma Stocks So Far in 2025. In this article, we are going to take a ...
In a report released today, Jonathan Woo from Phillip Securities maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), with a ...
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc.
Akero Therapeutics announced a public offering of over 5.3 million shares at $48 each, aiming for $350 million in proceeds. Akero Therapeutics, Inc. has announced a public offering of 5,333,420 ...
AKRO opened at $54.08 on Friday. Akero Therapeutics has a 12-month low of $15.32 and a 12-month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to ...
Akero Therapeutics, Inc. (NASDAQ:AKRO – Get Free Report) traded up 4.8% during mid-day trading on Wednesday after Morgan Stanley raised their price target on the stock from $46.00 to $96.00.
Akero Therapeutics, Brinker International And Viavi Are Among Top Mid Cap Gainers Last Week (Jan 27-Jan 31): Are The Others In Your Portfolio? Check out this week's top-performing mid-cap stocks ...
Chardan Capital analyst Michael Morabito reiterated a Buy rating on Akero Therapeutics (NASDAQ:AKRO) Inc on Wednesday, setting a price target of $81, which is ...
In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against other best performing pharma stocks so far in 2025. On February 20, Jared Holz ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results